Overview

Atrial Fibrillation Feasibility Certoparin Trial - AFFECT

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Certoparin
Heparin, Low-Molecular-Weight